

8 February 2024

## TrivarX Receives \$888k R&D Tax Incentive

**Perth, Australia, and Minneapolis, USA: TrivarX Limited** ('the Company') (ASX: TRI) is pleased to confirm the receipt of \$888,829.41 for its Research & Development (R&D) Tax Incentive for the 2022/23 financial year.

The refund payment relates to TrivarX's eligible expenditure in connection with the continuing development of its Sleep Analysis of Major Depressive Episode (SAMDE) Clinical Study, and the ongoing development and commencement of commercialisation of its sleep staging software, STAGER.

**This announcement is authorised for release by the Board of Directors of TrivarX Limited.**

**ENDS**

### Investor Enquiries:

[investors@medibio.com.au](mailto:investors@medibio.com.au)

+61 8 6189 1155

Henry Jordan – Six Degrees Investor Relations

[Henry.jordan@sdir.com.au](mailto:Henry.jordan@sdir.com.au)

+61 431 271 538

### About TrivarX Limited:

TrivarX (ASX: TRI) (OTCPINK: MDBIF) is a mental health technology company pioneering the use of objective measures to aid in the early detection and screening of mental health conditions. Through their Corporate Health product, the Company offers mental well-being solutions for businesses and are also developing products to serve the healthcare provider market. The Company was founded in Australia, with offices located in Perth (WA) and Minneapolis (MN, USA). TrivarX is listed on the Australian Securities Exchange Ltd and trades on the OTCQB Venture Market. Investors can find additional information on [www.otcm Markets.com](http://www.otcm Markets.com) and [www.asx.com.au](http://www.asx.com.au)